Phosphoinositide signalling system in platelets of schizophrenic patients and the effect of neuroleptic therapy
Language English Country Scotland Media print
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
10509868
DOI
10.1054/plef.1999.0081
PII: S0952327899900819
Knihovny.cz E-resources
- MeSH
- Antipsychotic Agents therapeutic use MeSH
- Time Factors MeSH
- Adult MeSH
- Phosphatidylinositol 4,5-Diphosphate metabolism MeSH
- Phosphatidylinositol Phosphates metabolism MeSH
- Phosphatidylinositols blood metabolism physiology MeSH
- Inositol 1,4,5-Trisphosphate blood physiology MeSH
- Phosphatidic Acids metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Phosphorus Radioisotopes MeSH
- Schizophrenia blood drug therapy MeSH
- Signal Transduction MeSH
- Blood Platelets chemistry drug effects physiology MeSH
- Calcium metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antipsychotic Agents MeSH
- Phosphatidylinositol 4,5-Diphosphate MeSH
- Phosphatidylinositol Phosphates MeSH
- Phosphatidylinositols MeSH
- Inositol 1,4,5-Trisphosphate MeSH
- Phosphatidic Acids MeSH
- phosphatidylinositol 4-phosphate MeSH Browser
- Phosphorus Radioisotopes MeSH
- Calcium MeSH
Alterations in the phosphoinositide signalling system have been proposed as a possible biological marker of schizophrenia. We studied the levels of inositol 1,4,5-trisphosphate (IP3), cytosolic Ca2+ concentrations ([Ca2+]i), and the incorporation of [32P]-orthophosphate into inositol phospholipids and phosphatidic acid (PA) in blood platelets of neuroleptic-treated schizophrenics in comparison with controls. The [Ca2+]i was significantly higher in platelets of one month neuroleptic-treated patients (155+/-5.8 nM) in comparison with controls (95+/-5.4 nM). Neuroleptic therapy decreased the [Ca2+]i, but even after long-term therapy it remained significantly higher (114+/-5.7 nM) than in controls. Differences were also found in the level of IP3 between controls (30+/-4.0 pmol/10(9) platelets), drug-free schizophrenics (52+/-9.0 pmol/10(9) platelets) and treated patients (50+/-6.0 pmol/10(9) platelets). The increased turnover of PA was observed in platelets of neuroleptic-treated schizophrenic patients. The study suggests that the regulation of calcium homeostasis and pathways involved in the phosphoinositide signalling system are altered in the platelets of schizophrenics. Neuroleptic therapy did not remove the observed changes in [Ca2+]i and IP3 levels.
References provided by Crossref.org